AbbVie (ABBV) Operating Margin (2012 - 2026)
AbbVie (ABBV) posted quarterly Operating Margin of 26.6% for Q1 2026, down 138.0% YoY from 69.99% in Q1 2025, and down 2.73% sequentially from 27.34% in Q4 2025.
AbbVie (ABBV) Operating Margin (2012 - 2026) Analysis & Trends
AbbVie has disclosed Operating Margin across 15 years of filings, most recently posting 26.6% for Q1 2026.
- In Q1 2026, Operating Margin fell 138.0% year-over-year to 26.6%; the TTM figure through Mar 2026 stood at 24.41% (up 685.0% YoY), while the FY2025 annual figure was 24.65%, up 843.0% from the prior year.
- Operating Margin fell to 26.6% in Q1 2026, from 27.34% in the prior quarter.
- Over the last five years, Operating Margin for ABBV reached as high as 36.39% in Q4 2022 and fell as low as 9.87% in Q4 2024.
- The 5-year median for Operating Margin is 26.6% (2026), against an average of 24.21%.
- Annual changes were most pronounced in 2024 — Operating Margin tumbled 3221 bps — and 2025, when it jumped 3721 bps.
- A 5-year view of Operating Margin shows it stood at 36.39% in 2022, then plunged by 39 bps to 22.34% in 2023, then tumbled by 144 bps to 9.87% in 2024, then surged by 377 bps to 27.34% in 2025, then decreased by 3 bps to 26.6% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 26.6%, 27.34%, and 12.07% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 47.98% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 26.44% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 26.60% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.51% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -286.83% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -11.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.60% |
| Dec 31, 2025 | 27.34% |
| Sep 30, 2025 | 12.07% |
| Jun 30, 2025 | 31.73% |
| Mar 31, 2025 | 27.98% |
| Dec 31, 2024 | -9.87% |
| Sep 30, 2024 | 26.49% |
| Jun 30, 2024 | 27.64% |
| Mar 31, 2024 | 22.73% |
| Dec 31, 2023 | 22.34% |
| Sep 30, 2023 | 16.38% |
| Jun 30, 2023 | 32.55% |
| Mar 31, 2023 | 22.64% |
| Dec 31, 2022 | 36.39% |
| Sep 30, 2022 | 31.08% |
| Jun 30, 2022 | 22.59% |
| Mar 31, 2022 | 34.84% |
| Dec 31, 2021 | 34.09% |
| Sep 30, 2021 | 30.02% |
| Jun 30, 2021 | 31.81% |